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While discrete point analysis (DPA) (e.g. peak power) is by far the most common 9 
method of analyzing movement data, it may have significant limitations because it 10 
ignores the vast majority of a signal’s data. In response, there has been a small but 11 
growing use of methods, such as functional data analysis (FDA), which allow an 12 
investigation of the underlying structure of the continuous signal and may therefore 13 
provide a more powerful analysis. However, a direct comparison between DPA and 14 
FDA has not been previously reported. PURPOSE: To directly compare DPA and 15 
FDA for the identification of performance determining factors for the 16 
countermovement jump (CMJ). METHODS: Twenty-five male participants performed 17 
15 CMJs, and the highest jump was selected for further analysis. Joint and whole 18 
body kinematic and kinetic measures were determined using position data (Vicon, 19 
250 Hz) and force plate data (AMTI, 1000Hz). Participants were divided into good 20 
(n=10) and poor (n=10) groups based on jump height. A t-test (α = 0.05) was 21 
performed on the timing and magnitude of key variables (DPA) and functional derived 22 
points (FDA) during the propulsion phase to examine differences between the 23 
groups. RESULTS: Both techniques found differences (p<0.05) in knee angular peak 24 
velocity, CoM peak velocity, CoM peak power and CoM work done. However, the 25 
FDA alone found significant higher (p<0.05) ankle moment (79 - 83%, peak at 67%), 26 
ankle power (54 - 67%, peak at 81%), knee angular velocity (28 - 100%), CoM 27 
velocity (56 - 100%), CoM power (49 – 91%) and a delay in CoM position (10 – 90%) 28 
and CoM velocity (10 - 60%) for the good performance group. Finally, the DPA alone 29 
found differences in ankle peak moment, ankle peak power and hip peak angular 30 
velocity. CONCLUSIONS: In contrast to FDA, DPA found three events which were 31 
not detected by FDA. However, only FDA was able to identify important differences in 32 
phases of the CMJ and explains differences between good and poor performance 33 
better than DPA. Finally, the ability to examine data with continuous techniques 34 
appears to provide a deeper insight into human movement than DPA. 35 
